{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:47:37Z","timestamp":1788457657049,"version":"build-2803163510"},"reference-count":143,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R21EY028279"],"award-info":[{"award-number":["R21EY028279"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY030472"],"award-info":[{"award-number":["R01EY030472"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Vascular-related retinal diseases dramatically impact quality of life and create a substantial burden on the healthcare system. Age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity are leading causes of irreversible blindness. In recent years, the scientific community has made great progress in understanding the pathology of these diseases and recent discoveries have identified promising new treatment strategies. Specifically, compelling biochemical and clinical evidence is arising that small-molecule modulation of peroxisome proliferator-activated receptors (PPARs) represents a promising approach to simultaneously address many of the pathological drivers of these vascular-related retinal diseases. This has excited academic and pharmaceutical researchers towards developing new and potent PPAR ligands. This review highlights recent developments in PPAR ligand discovery and discusses the downstream effects of targeting PPARs as a therapeutic approach to treating retinal vascular diseases.<\/jats:p>","DOI":"10.3390\/ijms21239251","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:59:00Z","timestamp":1607083140000},"page":"9251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-381X","authenticated-orcid":false,"given":"Xiaozheng","family":"Dou","sequence":"first","affiliation":[{"name":"Department of Chemistry &amp; Biochemistry, University of Notre Dame, Notre Dame, IN 46656, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3130-9890","authenticated-orcid":false,"given":"Adam S.","family":"Duerfeldt","sequence":"additional","affiliation":[{"name":"Department of Chemistry &amp; Biochemistry, University of Oklahoma, Norman, OK 73019, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"ref_1","unstructured":"Banyard, P., Dillon, G., Norman, C., and Winder, B. (2019). Essential Psychology, SAGE."},{"key":"ref_2","unstructured":"National Academies of Sciences, Engineering, and Medicine (2016). Making Eye Health a Population Health Imperative: Vision for Tomorrow, National Academies Press (US)."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajo.2017.07.022","article-title":"An analysis of medicare reimbursement to ophthalmologists: Years 2012 to 2013","volume":"182","author":"Han","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_4","unstructured":"Stone, W.L., Patel, B.C., Basit, H., and Salini, B. (2020). Retinopathy, StatPearls."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/bjophthalmol-2014-305561","article-title":"Incidence and treatment of retinopathy of prematurity in England between 1990 and 2011: Database study","volume":"99","author":"Painter","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"821592","DOI":"10.1155\/2008\/821592","article-title":"PPAR-alpha ligands as potential therapeutic agents for wet age-related macular degeneration","volume":"2008","author":"Del","year":"2008","journal-title":"PPAR Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11262-1","article-title":"A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration","volume":"10","author":"Handa","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16016","DOI":"10.1038\/sigtrans.2016.16","article-title":"Genetic and environmental factors strongly influence risk, severity and progression of age-related macular degeneration","volume":"1","author":"Wang","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ajo.2007.09.008","article-title":"The epidemiology of retinal reticular drusen","volume":"145","author":"Klein","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ophtha.2010.01.027","article-title":"Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration","volume":"117","author":"Zweifel","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1006\/exer.2001.1094","article-title":"Complement activation and inflammatory processes in drusen formation and age-related macular degeneration","volume":"73","author":"Johnson","year":"2001","journal-title":"Exp. Eye Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1167\/iovs.05-0767","article-title":"Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen","volume":"46","author":"Johnson","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8374647","DOI":"10.1155\/2018\/8374647","article-title":"Age-related macular degeneration: New paradigms for treatment and management of AMD","volume":"2018","author":"Zenteno","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: Angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"Am. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal diseases","volume":"331","author":"Aiello","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9394(14)72066-5","article-title":"Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes","volume":"122","author":"Frank","year":"1996","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","first-page":"2603","article-title":"Inolvement of adenosine in retinal ischemia. Studies on the rat","volume":"37","author":"Larsen","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_22","first-page":"855","article-title":"Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes","volume":"37","author":"Lopez","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections","volume":"31","author":"Ringens","year":"2011","journal-title":"Retina"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kaiser, A.B., Zhang, N., and Van der Pluijm, W. (2018). Global prevalence of type 2 diabetes over the next ten years (2018\u20132028). Diabetes, 67.","DOI":"10.2337\/db18-202-LB"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_28","unstructured":"(2020, October 18). WHO Calls for Global Action to Halt Rise in and Improve Care for People with Diabetes. Available online: https:\/\/www.who.int\/news-room\/detail\/06-04-2016-world-health-day-2016-who-calls-for-global-action-to-halt-rise-in-and-improve-care-for-people-with-diabetes."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.biocel.2009.10.006","article-title":"Proliferative retinopathies: Angiogenesis that blinds","volume":"42","author":"Sapieha","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bjo.80.2.168","article-title":"Distribution of TNF-alpha and it\u2019s reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy","volume":"80","author":"Limb","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1096\/fj.01-0707fje","article-title":"Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression","volume":"16","author":"Joussen","year":"2002","journal-title":"FASEB J."},{"key":"ref_32","first-page":"642","article-title":"Enhanced expression of intracellular adhesions molecule-1 and p-selectin in diabetic human retina and choroid","volume":"147","author":"McLeod","year":"1995","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1167\/iovs.02-0807","article-title":"VEGF164 is proinflammatory in the diabetic retina","volume":"44","author":"Ishida","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cai, X., and McGinnis, J.F. (2016). Diabetic retinopathy: Animal models, therapies, and perspectives. J. Diabetes Res., 2016.","DOI":"10.1155\/2016\/3789217"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IIO.0b013e31819fd164","article-title":"Pathophysiology of diabetic macular edema","volume":"49","author":"Singh","year":"2009","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.preteyeres.2015.04.003","article-title":"Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence","volume":"48","author":"Simo","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2337\/dc13-2002","article-title":"Ocular anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy","volume":"37","author":"Sundstrom","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMct0908432","article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy","volume":"365","author":"Bressler","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000330174","article-title":"Understanding retinopathy of prematurity: Update on pathogenesis","volume":"100","author":"Rivera","year":"2011","journal-title":"Neonatology"},{"key":"ref_41","unstructured":"(2020, October 18). Retinopathy of Prematurity, Available online: https:\/\/nei.nih.gov\/health\/rop\/rop."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-017-0943-1","article-title":"Retinopathy of prematurity: Inflammation, choroidal degeneration, and novel promising therapeutic strategies","volume":"14","author":"Rivera","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.semperi.2019.05.009","article-title":"Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity","volume":"43","author":"Aranda","year":"2019","journal-title":"Semin. Perinatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Pertl, L., Steinwender, G., Mayer, C., Hausberger, S., P\u00f6schl, E.-M., Wackernagel, W., Wedrich, A., El-Shabrawi, Y., and Haas, A. (2015). A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129383"},{"key":"ref_48","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity","volume":"54","author":"McCloskey","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18316","DOI":"10.1038\/srep18316","article-title":"Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2(Akita) diabetic mouse","volume":"5","author":"Hombrebueno","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ajpath.2012.12.032","article-title":"VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma","volume":"182","author":"Foxton","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1126\/science.284.5415.757","article-title":"Orphan nuclear receptors: Shifting endocrinology into reverse","volume":"284","author":"Kliewer","year":"1999","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs:\u2009 from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(95)90200-7","article-title":"The RXR Heterodimers and orphan receptors","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): Development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.18632\/aging.101031","article-title":"PPARbeta\/delta selectively regulates phenotypic features of age-related macular degeneration","volume":"8","author":"Choudhary","year":"2016","journal-title":"Aging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1007\/s00018-014-1709-x","article-title":"Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration","volume":"71","author":"Malek","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/1087057116659856","article-title":"Rethinking nuclear receptors as potential therapeutic targets for retinal diseases","volume":"21","author":"Choudhary","year":"2016","journal-title":"J. Biomol. Screen."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ho, S.Y., Kwan, Y.P., Qiu, B., Tan, A., Murray, H.L., Barathi, V.A., Tan, N.S., Cheung, C.M.G., Wong, T.Y., and Wahli, W. (2020). Investigating the role of PPARbeta\/delta in retinal vascular remodeling using Pparbeta\/delta-deficient mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124403"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1167\/iovs.13-11608","article-title":"Peroxisome proliferator-activated receptor-\u03b2\/\u03b4 regulates angiogenic cell behaviors and oxygen-induced retinopathy","volume":"54","author":"Capozzi","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Tobita, Y., Arima, T., Nakano, Y., Uchiyama, M., Shimizu, A., and Takahashi, H. (2020). Peroxisome proliferator-activated receptor beta\/delta agonist suppresses inflammation and promotes neovascularization. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155296"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1167\/iovs.14-14217","article-title":"Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-beta\/delta","volume":"55","author":"Suarez","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_64","first-page":"568","article-title":"RNA-seq identifies a role for the PPAR\u03b2\/\u03b4 inverse agonist GSK0660 in the regulation of TNF\u03b1-induced cytokine signaling in retinal endothelial cells","volume":"21","author":"Savage","year":"2015","journal-title":"Mol. Vis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"275435","DOI":"10.1155\/2015\/275435","article-title":"Role of peroxisome proliferator-activated receptor gamma in ocular diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"J. Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-12-46","article-title":"The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy","volume":"12","author":"Treacy","year":"2012","journal-title":"BMC Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"686525","DOI":"10.1155\/2013\/686525","article-title":"Molecular implications of the PPARs in the diabetic eye","volume":"2013","author":"Ciudin","year":"2013","journal-title":"PPAR Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2011.01411.x","article-title":"Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-gamma-related pharmacology","volume":"165","author":"Song","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_69","first-page":"83","article-title":"Involvement of the ubiquitin-proteasome system in the expression of extracellular matrix genes in retinal pigment epithelial cells","volume":"13","author":"Verwoert","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1210\/me.2010-0392","article-title":"Research resource: Nuclear receptor atlas of human retinal pigment epithelial cells: Potential relevance to age-related macular degeneration","volume":"25","author":"Dwyer","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s11064-015-1517-1","article-title":"DHA inhibited AGEs-induced retinal microglia activation via suppression of the PPARgamma\/NFkappaB pathway and reduction of signal transducers in the AGEs\/RAGE axis recruitment into lipid rafts","volume":"40","author":"Wang","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fphar.2017.00783","article-title":"Ginsenoside-Rb1-mediated anti-angiogenesis via regulating PEDF and miR-33a through the activation of PPAR-gamma pathway","volume":"8","author":"Lu","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1783564","DOI":"10.1155\/2020\/1783564","article-title":"Association of peroxisome proliferator-activated receptors (PPARs) with diabetic retinopathy in human and animal models: Analysis of the literature and genome browsers","volume":"2020","author":"Tajnsek","year":"2020","journal-title":"PPAR Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2020.1703952","article-title":"Peroxisome proliferator-activated receptor agonists and antagonists: A patent review (2014\u2013present)","volume":"30","author":"Takada","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1021\/acs.jmedchem.0c00654","article-title":"Photohormones enable optical control of the peroxisome proliferator-activated receptor gamma (PPARgamma)","volume":"63","author":"Hinnah","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2337\/diab.18.5.285","article-title":"A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy","volume":"18","author":"Harrold","year":"1969","journal-title":"Diabetes"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1307211110","article-title":"Pathogenic role of diabetes-induced PPAR-\u03b1 down-regulation in microvascular dysfunction","volume":"110","author":"Hu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ajpath.2014.06.021","article-title":"Peroxisome proliferator-activated receptor alpha protects capillary pericytes in the retina","volume":"184","author":"Ding","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1167\/iovs.13-13127","article-title":"Protective and antioxidant effects of PPARalpha in the ischemic retina","volume":"55","author":"Moran","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.2337\/db16-0426","article-title":"Interaction of PPARalpha with the canonic Wnt pathway in the regulation of renal fibrosis","volume":"65","author":"Cheng","year":"2016","journal-title":"Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2337\/diabetes.55.04.06.db05-1329","article-title":"Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor","volume":"55","author":"Park","year":"2006","journal-title":"Diabetes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-67579-1","article-title":"PPAR\u03b1 activation directly upregulates thrombomodulin in the diabetic retina","volume":"10","author":"Shiono","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"FIELD Study Investigators (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 366, 1849\u20131861.","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138161209787315701","article-title":"Fibrates and microvascular complications in diabetes\u2014Insight from the FIELD study","volume":"15","author":"Ansquer","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2337\/db11-0413","article-title":"Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models","volume":"62","author":"Chen","year":"2013","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Nakano, Y., Uchiyama, M., Arima, T., Nagasaka, S., Igarashi, T., Shimizu, A., and Takahashi, H. (2018). PPARalpha agonist suppresses inflammation after corneal alkali burn by suppressing proinflammatory cytokines, MCP-1, and nuclear translocation of NF-kappaB. Molecules, 24.","DOI":"10.3390\/molecules24010114"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome analysis of K-877 (a novel selective PPAR\u03b1 modulator (SPPARM\u03b1))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Tanaka","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11892-016-0786-7","article-title":"Fenofibrate and diabetic retinopathy","volume":"16","author":"Knickelbein","year":"2016","journal-title":"Curr. Diabates Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): The next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","article-title":"Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2018.03.135","article-title":"Molecular association model of PPARalpha and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMalpha","volume":"499","author":"Yamamoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kawasaki, M., Kambe, A., Yamamoto, Y., Arulmozhiraja, S., Ito, S., Nakagawa, Y., Tokiwa, H., Nakano, S., and Shimano, H. (2020). Elucidation of molecular mechanism of a selective PPARalpha modulator, pemafibrate, through combinational approaches of X-ray crystallography, thermodynamic analysis, and first-principle calculations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010361"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., and Kodama, T. (2019). Gene expression profiles induced by a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) pemafibrate. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225682"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","article-title":"Effects of K-877, a novel selective PPARalpha modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice","volume":"133","author":"Takei","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Tomita, Y., Ozawa, N., Miwa, Y., Ishida, A., Ohta, M., Tsubota, K., and Kurihara, T. (2019). Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235878"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1167\/iovs.16-21402","article-title":"Therapeutic effects of a novel agonist of peroxisome proliferator-activated receptor alpha for the treatment of diabetic retinopathy","volume":"58","author":"Deng","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.bmcl.2018.03.010","article-title":"Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPAR\u03b1 selective agonists: New leads for oculovascular conditions","volume":"28","author":"Dou","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1021\/acs.jmedchem.9b01189","article-title":"Evolution of a 4-benzyloxy-benzylamino chemotype to provide efficacious, potent, and isoform selective PPARalpha agonists as leads for retinal disorders","volume":"63","author":"Dou","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2165\/00003495-199040020-00007","article-title":"Fenofibrate","volume":"40","author":"Balfour","year":"1990","journal-title":"Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Hong, F., Xu, P., and Zhai, Y. (2018). The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082189"},{"key":"ref_109","unstructured":"Jain, M., Joharapurkar, A.A., and Patel, V.J. (2017). Dual PPAR Modulators for the Treatment of Diabetic Retinopathy and Diabetic Eye Diseases. (WO 2017\/089980 Al)."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"103167","DOI":"10.1155\/2008\/103167","article-title":"Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists","volume":"2008","author":"Oleksiewicz","year":"2008","journal-title":"PPAR Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fievet","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/13543776.2016.1182500","article-title":"Fatty acid binding protein (FABP) inhibitors: A patent review (2012\u20132015)","volume":"26","author":"Wang","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejmech.2017.07.022","article-title":"Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review","volume":"138","author":"Floresta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fncel.2019.00162","article-title":"Fatty acid signaling mechanisms in neural cells: Fatty acid receptors","volume":"13","author":"Cavazzutti","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Geiger, O. (2017). Fatty acid-binding proteins, a family of lipid chaperones. Biogenesis of Fatty Acids, Lipids and Membranes, Springer.","DOI":"10.1007\/978-3-319-43676-0"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11745-007-3111-z","article-title":"Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription","volume":"43","author":"Schroeder","year":"2008","journal-title":"Lipids"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygeno.2008.08.003","article-title":"A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: Transcription in rat retina and testis","volume":"92","author":"Liu","year":"2008","journal-title":"Genomics"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1167\/iovs.15-18542","article-title":"Characterization of fatty acid binding protein 7 (FABP7) in the murine retina","volume":"57","author":"Su","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1073\/pnas.051619898","article-title":"Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha\u2014And gamma-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus","volume":"98","author":"Wolfrum","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1074\/jbc.RA118.006848","article-title":"A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor alpha agonists","volume":"294","author":"Patil","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"938401","DOI":"10.1155\/2013\/938401","article-title":"Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs","volume":"2013","author":"Velkov","year":"2013","journal-title":"PPAR Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"13895","DOI":"10.1074\/jbc.M114.605998","article-title":"Fatty acid-binding proteins 1 and 2 differentially modulate the activation of peroxisome proliferator-activated receptor alpha in a ligand-selective manner","volume":"290","author":"Hughes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1128\/MCB.22.14.5114-5127.2002","article-title":"Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription","volume":"22","author":"Tan","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S1357-2725(00)00046-7","article-title":"Differential effects of PPAR\u03b1 activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver","volume":"32","author":"Motojima","year":"2000","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1042\/BJ20031340","article-title":"Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins","volume":"382","author":"Schachtrup","year":"2004","journal-title":"Biochem. J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","article-title":"Nuclear receptors, RXR, and the big bang","volume":"157","author":"Evans","year":"2014","journal-title":"Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbalip.2011.09.014","article-title":"The retinoid X receptors and their ligands","volume":"1821","author":"Dawson","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10626","DOI":"10.1073\/pnas.0913545107","article-title":"Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression","volume":"107","author":"Nunez","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nn.2702","article-title":"Retinoid X receptor gamma signaling accelerates CNS remyelination","volume":"14","author":"Huang","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.febslet.2011.03.048","article-title":"Regulation of remyelination in multiple sclerosis","volume":"585","author":"Hanafy","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_133","first-page":"1016","article-title":"Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis","volume":"8","author":"Chandraratna","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer\u2019s disease","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"10725","DOI":"10.1073\/pnas.1700785114","article-title":"Retinoid X receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism","volume":"114","author":"Kiss","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1586\/14737140.4.2.180","article-title":"Bexarotene: A clinical review","volume":"4","author":"Farol","year":"2004","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/jm00044a014","article-title":"Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids","volume":"37","author":"Boehm","year":"1994","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1021\/jm00016a018","article-title":"Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells","volume":"38","author":"Boehm","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9013","article-title":"Structural mechanism for signal transduction in RXR nuclear receptor heterodimers","volume":"6","author":"Kojetin","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0960-0760(02)00066-3","article-title":"Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha","volume":"81","author":"Mukerjee","year":"2002","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"110436","DOI":"10.1016\/j.mce.2019.04.016","article-title":"Alternative retinoid X receptor (RXR) ligands","volume":"491","author":"Krezel","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1021\/acs.jmedchem.8b01848","article-title":"Tuning nuclear receptor selectivity of Wy14,643 towards selective retinoid X receptor modulation","volume":"62","author":"Pollinger","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/358771a0","article-title":"Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors","volume":"358","author":"Kliewer","year":"1992","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/9251\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:23Z","timestamp":1760179283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/9251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":143,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21239251"],"URL":"https:\/\/doi.org\/10.3390\/ijms21239251","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}